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WHAT THIS PAPER ADDS?
 This is the ﬁrst preliminary ex-vivo study evaluating histopathological changes in the vein wall achieved by the use of different
concentrations of foam sclerosants. Foam sclerotherapy exerts a certain amount of pathological damage even at the lowest
concentration (0.5%). Therefore it seems to be a concentration-independent procedure in 5e10 mm caliber ex-vivo veins, although
a 1% concentration was found to be near signiﬁcantly the most injurious to the vein wall. Direct extrapolation of these ﬁndings to
clinical settings needs further validation with in-vivo clinical studies.a r t i c l e i n f o
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Background: Foam sclerosants are widely used in sclerotherapy and have been accepted as more effective
than the liquid form; however, there is no consensus about the most applicable and effective
concentration.
Objective: The aim of this study was to investigate the histopathological changes caused by various
widely used concentrations of foam sclerosant.
Methods: Fifty-six varicose vein segments of 5e10 mm diameter were gently resected and exposed to
various concentrations of foam sclerosant (0.5%, 1%, 2%, 3%) for 5 min, and were then prepared for
routine histopathological examination. A total damage scoring system, including the presence of
endothelial swelling, intimal thickening, cellular vacuolization in the muscle layer, edema in the
tunica media and extent of necrosis, was established.
Results: The total damage score of the foam sclerosant groups was signiﬁcantly higher than that of the
control group (median 2.75 vs 1, p ¼ 0.007). The highest damage score was achieved by 1% and 2% foam
sclerosants (3.5 and 2.5). No signiﬁcant difference was found among the different concentrations of
sclerosant, although the 1% group caused more severe damage at a near signiﬁcant level (p ¼ 0.074).
Conclusion: Signiﬁcant pathological damage can be caused by even the lowest doses of foam sclerosant.
The most injurious concentrations were found to be 1% and 2%, morphologically. A working concen-
tration of 1% could thus be preferable to 0.5%, especially in larger veins. Further in-vivo studies are
needed in order to validate these ﬁndings.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Sclerotherapy has been used for the treatment of varicose veins
since Linser1 ﬁrst applied a liquid sclerosant, but the outcome of@hotmail.com (A. Erkin).
ciety for Vascular Surgery. Publishethis method was not satisfactory. In 1944, Orbach2,3 published the
air block method in varicose vein sclerotherapy. He developed the
foam form of sclerosant agent by shaking sodium tetradecyl
sulfate.3 Recently, foam sclerosants were proved to be more effec-
tive than the liquid form.3e6 Of particular interest, in the compar-
ative study of Hamel-Desnos et al.,5 foam sclerosant applied to the
greater saphenous vein achieved an 84% (38 of 45) success rate
compared to 40% (17 of 43) from using liquid sclerosant.d by Elsevier Ltd. All rights reserved.
Table 1
Pathological grading system.
Pathological ﬁndings Score
Endothelial swelling Absent 0
Present 1
Necrosis Absent 0
Focal 1
Widespread 2
Edema of tunica media Absent 0
Present 1
Vacuolization of smooth muscle Absent 0
Present 1
Intimal thickening Absent 0
Present 1
Total damage score 0e6
A. Erkin et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 593e597594Morphologically, subendothelial edema and necrosis were
observed in an in-vivo study after 1e2 ml of 3% sodium tetradecyl
sulfate foamwas injected into the great saphenous vein.7 However,
data about morphological changes caused by different concentra-
tions of foam sclerosant are lacking.
In 2003 and 2006, experts on sclerotherapy met to standardize
treatment with foam sclerotherapy. In 2003, it was stated that
lower concentrations of foam sclerosant could be used for the
treatment of varicose veins, instead of liquid sclerosant.2 Then, in
2006, after the experts agreed that both the efﬁcacy and tolerability
of foam sclerotherapy depend on the concentration and volume
injected, they published a consensus suggesting the applicable
concentrations of foam sclerosant to varicose veins of different
diameters. However, reliable clinical data allowing the selection of
appropriate concentrations were still scarce.8 In a randomized
double-blind trial in which 148 patients with great saphenous vein
reﬂux (saphenous trunk diameter 4e8 mm) were randomized to
undergo ultrasound-guided foam sclerotherapy using either 1% or
3% polidocanol foam in a single session, clinical success rates after 3
weeks were not statistically different.9
We conducted a preliminary ex-vivo study investigating the
degree of histopathological changes in the vein wall exerted by
various widely used concentrations of foam sclerosant.
Material and Methods
Experimental design
Appropriate varicose vein segments of 5e10 mm diameter were
gently resected through stab phlebectomy incisions and put into
0.9% NaCl solution. Each vein segment was divided into ﬁve equal
pieces. In order to provide complete contact between foam
sclerosant and the endothelium, each vein segment was cut along
its full length. One of the pieces was placed in 10% formalin
solution (control segment) and the rest were subjected to foam
sclerosant at different concentrations. We used 0.5%, 1%, 2% and
3% concentrations of lauromacrogol 400 (Polydocanol, Kreussler
& Co. GmbH). Foam was generated using the Tessari technique10
with 2 ml of sclerosant and 5 ml of air.11 Liquid sclerosant and air
were mixed for 20 passages while the aperture in the three-way
stop cock was narrowed to generate micro foam. Each piece of
vessel was immersed into the selected concentration of foam
sclerosant. The vein segments were soaked in sclerosant for 5 min.
The speciﬁcation of the durationwas described elsewhere.12 A ﬁxed
contact time of 5 min was employed because the foam was
completely reverting to liquid by 287 s in 0.5%, 302 s in 1%, 362 s in
2% and 450 s in 3% concentration. After a 5-min exposure, the vein
segments werewashed out with isotonic saline solution and placed
in 10% buffered formalin solution.
Pathological examination and grading
Fragments of varicose veins processed with different concen-
trations of sclerosant were ﬁxed in 10% buffered formalin overnight
and embedded in parafﬁn blocks separately. H&E staining was
performed on the 5 micron thick cross-sections of the varicose
veins. Slides were examined by a single pathologist (KK) who was
blinded to the applied concentrations of sclerosant.
Microscopically, we evaluated the presence of endothelial
swelling, intimal thickening, smooth muscle vacuolization, edema
in tunica media and extent of necrosis. A total damage scoring
system reﬂecting the damage to the vein wall was established: the
absence of a pathological ﬁnding was scored as 0 while the pres-
ence was scored as 1. Exceptionally, necrosis was scored 0e2
depending on its extent, due to its relative importance inevaluation of tissue damage. Finally, a total damage score was
calculated using the sum of scores gained from pathological ﬁnd-
ings (Table 1).
Statistics
Analyses were performed with SPSS (Statistical Package for
Social Sciences) for Windows (Version 15.0.0; SPSS Inc). Using the
KolmogoroveSmirnov test, all parameters showed a non-normal
distribution. Intergroup comparison of quantitative data was per-
formed using the KruskaleWallis test and the parameter leading to
difference was investigated by the ManneWhitney U-test. P < 0.05
was regarded as signiﬁcant. Chi square and Fisher’s exact test were
used to compare qualitative variables.
Results
Diameters of 56 varicose vein segments ranged between 5 and
10 mm. Control, 0.5%, 1% and 2% groups consisted of 12 vein
segments, whereas 8 vein segments were available for the 3%
group.
The distribution of histological ﬁndings among control and
different concentration groups is summarized in Table 2. In the
control group, the morphological examination of vessel sections
was near normal (Fig. 1B). The sclerosant group (all concentration
groups together) showed some of the investigated pathological
changes, including endothelial swelling (Fig. 1A), necrosis (Fig. 2)
and intimal thickening (Fig. 3) more frequently than the control
group (Table 2). Vacuolization (Fig. 4) and edema did not differ
signiﬁcantly. When we compared the different concentration
groups, there was no statistically signiﬁcant difference regarding
the presence of a single histological parameter (endothelial thick-
ening, necrosis, vacuolization, edema, intimal thickening), except
for the presence and extent of necrosis, which is more likely to be
encountered with higher concentrations of foam sclerosant (Fig. 2).
Median damage score of the sclerosant group was signiﬁcantly
higher than that of the control group (2.75 vs 1, p ¼ 0.007). The
highest damage score was achieved by 1% and 2% sclerosants;
however, divergent concentrations of sclerosant ranging between
0.5% and 3% did not alter morphology signiﬁcantly (Table 3). It
should also be mentioned that 1% foam sclerosant was the most
effective concentration, exerting the most severe damage on the
vein wall at a statistically near signiﬁcant level (p ¼ 0.074,
compared to 0.5%).
Discussion
In this ﬁrst ex-vivo study to compare the morphological effects
of different foam sclerosant concentrations, we have found that
Table 2
Distribution of histopathological ﬁndings.
Histological parameters Total n (%) Control n (%) Sclerosant n (%) Pa 0.5% n (%) 1% n (%) 2% n (%) 3% n (%) Pb
Endothelial swelling Absent 32 (57) 10 (83) 22 (50) .040 8 (67) 4 (33) 6 (50) 4 (50) .136
Present 24 (43) 2 (17) 22 (50) 4 (33) 8 (67) 6 (50) 4 (50)
Necrosis Absent 25 (45) 9 (75) 16 (36) .013 6 (50) 3 (25) 5 (42) 2 (25) .086
Focal 23 (41) 3 (25) 20 (46) 6 (50) 5 (42) 4 (33) 5 (63)
Widespread 8 (14) 0 (0) 8 (18) 0 (0) 4 (33) 3 (25) 1 (12)
Vacuolization Absent 34 (61) 10 (83) 24 (55) .073 7 (58) 6 (50) 6 (50) 5 (63) .438
Present 22 (39) 2 (17) 20 (45) 5 (42) 6 (50) 6 (50) 3 (38)
Edema Absent 33 (59) 9 (75) 24 (55) .206 6 (50) 4 (33) 8 (67) 6 (75) .194
Present 23 (41) 3 (25) 20 (45) 6 (50) 8 (67) 4 (33) 2 (25)
Intimal thickening Absent 36 (64) 11 (92) 25 (57) .045 7 (58) 5 (42) 8 (67) 5 (63) .146
Present 20 (36) 1 (8) 19 (43) 5 (42) 7 (58) 4 (33) 3 (37)
a Control vs sclerosants combined, ManneWhitney U-test.
b Control vs different concentrations of sclerosant (0.5%, 1%, 2% and 3%), KruskaleWallis test.
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the concentration of foam sclerosant, starting from even the lowest
concentration of 0.5%. At the Second European Consensus Meeting
on Foam Sclerotherapy, experts came together to standardize the
process of foam sclerotherapy.8 According to participants’ personal
experiences, some suggestions were given for the two most
commonly used sclerosant agents, polidocanol and tetradecyl
sulfate. They pointed out that the diameter of the vein is an
important determinant for the selection of the appropriate
concentration of foam sclerosant. On the other hand, there are
some controversial data about the importance of concentration.
Hamel-Desnos et al.9 reported in a functional in-vivo study that
there was no statistically signiﬁcant difference between the clinical
success rates of 1% and 3% polidocanol foam after a 2-year follow-
up. Similar results were also noted by Ikponmwosa et al.12 Our data
mainly agree with those of Ikponmwosa et al. and Hamel-Desnos
et al. in indicating that the effectiveness of foam sclerotherapy is
independent of the concentration used, as even the lowest
concentration led to signiﬁcant damage to the vein wall. It is also
worth mentioning that our study demonstrated 1% foam sclerosant
to be the most effective concentration in terms of the pathological
damage it exerted, compared to the higher doses of 2% and 3%.
These results suggest that the applied concentration of foam scle-
rosant can be adjusted as low as possible, regardless of the caliber
of the varicose veins, since the concentration used did not signiﬁ-
cantly alter the severity of morphological damage and thus possibly
the clinical outcome. Furthermore, using a low concentration of
sclerosant may contribute to a decrease in complications and the
total cost of the procedure. However, these results should beFigure 1. Note that endothelial nuclei of 2% sclerosant group (A) are hyperchromatic, enlar
lining (B). H&E, 400.validated by clinical studies, since the usage of clinically ineffective
concentrations may lead to re-treatment and drive the cost up.
Histomorphological changes caused by sclerotherapy were
previously described by Orsini and Brotto.7 In their in-vivo study,
3% sodium tetradecyl sulfate was injected into the proximal portion
of the great saphenous vein. The saphenous tract was divided into
three portions and removed after 2, 15 and 30 min for histopath-
ological examination. Complete absence of endothelial cells and
diffuse subendothelial edema were seen on vein walls even after
2 min. The saphena sections taken after 15 min showed larger areas
of necrosis, also involving tunica media, and after 30 min early
venous sclerosis, early parietal cover and shrinkage of the lumen
were seen. However, these histological changes represent not only
the effects of foam sclerosant but also the liquid form, since
Ikponmwosa et al.12 realized that foam sclerosant couldn’t remain
stable and completely reverted to liquid form within 300 s. Simi-
larly, in our study, we realized that the foam completely reverted to
liquid in a given amount of time for each concentration, and set the
contact time of the experiment accordingly. In the study of Orsini
and Brotto, histopathological changes seen at 15 and 30 min rep-
resented the cumulative effect of foam sclerosant and mostly the
reverted liquid formwithout any foam left. In the current study, the
pathological vascular changes were solely due to foam sclerosant or
foam plus the reverted liquid form, but not to the liquid form
without foam.
On histopathological examination, we realized that multiple
ﬁndings were encountered in the same vessel wall, even in
different sections. Therefore, we established a scoring system to
sum up all histopathological data and quantify theged and show hobnail-like extension toward lumen, compared to normal endothelial
Figure 2. Prominent widespread necrosis is seen along the luminal border charac-
terized by ﬁbrin (arrowhead) and apoptotic endothelial cells (arrow). Necrosis was
more likely to be encountered in vessels exposed to sclerosant. H&E, 200.
Figure 4. Vacuolization of smooth muscle cells. H&E, 400.
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groups. Quantitatively, no statistical signiﬁcance was determined
among the foam sclerosant groups of different concentrations,
although we obtained a signiﬁcant difference between the control
and foam sclerosant groups overall.
There are several limitations to our study. First of all, as soon as
we removed the varicose veins for the application of sclerosant ex-
vivo, we inevitably ignored the physiochemical effects of blood,
which certainly affect the contact between foam sclerosant and
vein wall, so we were unable to assess clinical outcomes directly.Figure 3. Intimal thickening (arrow) with edema is accompanied by prominent
endothelial swelling and irregularity in elastic lamina (arrowheads). H&E, 200; inlet
H&E, 1000.The conditions would be extremely different in the clinical situa-
tion, where blood is ﬂowing through the vein and only the endo-
thelium, instead of the whole vein wall, is subjected to foam
sclerosant. Even so, we are also aware of the studies that revealed
the insigniﬁcance of clinical outcome differences between foam
concentrations.9,12 In addition, at the consensus meeting in 2006,6
experts listed other important determinants, such as access loca-
tion, access material, preparation of foam, and especially foam
volume per injection, that may directly affect the success of the
process. Secondly, sclerosant was applied to the vein segment after
its removal from the patient. Even thoughwe tried to bring the vein
segment and sclerosant together as soon as possible, there couldTable 3
Comparison of total damage scores between control and all sclerosant
concentrations.
Total Damage Score 
Mean ± SD Median aP
Control 0.91 ± 0.90 1 
0.5% 2.16 ± 1.52 2 
1% 3.50 ± 1.83 3.5 
2% 2.50 ± 1.56 3 
3% 2.37 ± 1.50 2.5 
 .272 
.007 
Control e 0.5% bP ¼ 0.032
Control e 1% bP ¼ 0.001
Control e 2% bP ¼ 0.013
Control e 3% bP ¼ 0.023
0.5% e 1% bP ¼ 0.074
0.5% e 2% bP ¼ 0.536
0.5% e 3% bP ¼ 0.752
1% e 2% bP ¼ 0.197
1% e 3% bP ¼ 0.169
2% e 3% bP ¼ 0.751
a KruskaleWallis test.
b ManneWhitney U-test.
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and lack of effective contact of sclerosant with vein wall, which
could alter the results. Thirdly, as the details of the mechanism by
which foam sclerosants act on vessel walls are not well known,
minor differences between experimental models are inevitable. For
example, we applied foam sclerosant for 5 min as described
before.12 However, it has been reported that the half time of poli-
docanol foam is around 100 s for 0.5% and 1% concentrations,
suggesting that a shorter duration of foam application is required.13
Wollmann14 also pointed out that the stability, and thus the
effectiveness and safety, of the foam depends on not only the foam
half time, but also the drainage time and coalescence time, and
therefore the duration of foam stability remains below 50 s under
the optimum air-to-liquid ratio of foam sclerosant. Even syringe
size may affect the properties of foam.15 As a result, it would be
interesting to see the morphological results of an in-vivo study,
considering the variables mentioned above, summarized mainly
from the studies of Rao and Goldman13 and Wollmann.14 Lastly,
there are well-known limitations of histopathological examination
studies. Nevertheless, this is the ﬁrst study to compare the effects of
different concentrations of foam sclerosant, and we believe that
these results will be preliminary for future experiments.
Conclusion
In routine practice, a 0.5% or 1% concentration of foam sclerosant
is preferred for vessels less than 5mm in diameter, while 2% and 3%
concentrations are used for vessels larger than 5mm in diameter. In
the current ex-vivo study, we were unable to demonstrate any
statistically signiﬁcant results among different foam concentrations
on 5e10 mm diameter vessels in terms of pathological damage.
However, due to the near signiﬁcant difference between the
outcomes of 0.5% and 1% foam sclerosants, the use of 1% foam
sclerosant instead of 0.5% may be preferable. Again, 1% foam scle-
rosant may be preferred to 2% or 3% in larger vessels, as it exerts
more severe damage on the veinwall. Further studies are necessary
to validate our ﬁndings.
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